bluebird bio, Inc. (NASDAQ:BLUE) insider David Davidson sold 1,200 shares of the company’s stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $100.49, for a total transaction of $120,588.00. Following the sale, the insider now directly owns 16,077 shares of the company’s stock, valued at $1,615,577.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Davidson also recently made the following trade(s):

  • On Wednesday, July 5th, David Davidson sold 5,000 shares of bluebird bio stock. The shares were sold at an average price of $105.28, for a total transaction of $526,400.00.
  • On Monday, June 5th, David Davidson sold 1,000 shares of bluebird bio stock. The shares were sold at an average price of $90.00, for a total transaction of $90,000.00.

bluebird bio, Inc. (BLUE) traded up 0.90% during trading on Tuesday, reaching $94.85. The company had a trading volume of 910,022 shares. The company has a 50 day moving average price of $97.43 and a 200 day moving average price of $83.86. The company’s market capitalization is $3.88 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.76) by $0.08. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. The business had revenue of $6.83 million for the quarter, compared to analyst estimates of $1.51 million. On average, equities analysts forecast that bluebird bio, Inc. will post ($6.72) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/bluebird-bio-inc-blue-insider-sells-120588-00-in-stock.html.

Large investors have recently made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI purchased a new stake in shares of bluebird bio during the first quarter worth about $588,000. Usca Ria LLC purchased a new stake in shares of bluebird bio during the first quarter worth about $707,000. Great West Life Assurance Co. Can raised its stake in shares of bluebird bio by 28.5% in the first quarter. Great West Life Assurance Co. Can now owns 4,509 shares of the biotechnology company’s stock worth $409,000 after buying an additional 1,000 shares in the last quarter. Reynders McVeigh Capital Management LLC raised its stake in shares of bluebird bio by 40.3% in the first quarter. Reynders McVeigh Capital Management LLC now owns 7,535 shares of the biotechnology company’s stock worth $685,000 after buying an additional 2,165 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of bluebird bio by 42.1% in the first quarter. Russell Investments Group Ltd. now owns 33,823 shares of the biotechnology company’s stock worth $3,074,000 after buying an additional 10,027 shares in the last quarter.

A number of analysts have commented on BLUE shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a research note on Friday, March 24th. Maxim Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Friday, June 2nd. BTIG Research reaffirmed a “buy” rating and set a $112.00 price objective on shares of bluebird bio in a research note on Thursday, June 1st. Standpoint Research started coverage on shares of bluebird bio in a research note on Tuesday, May 30th. They set a “buy” rating and a $110.00 price objective for the company. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $108.00 price objective on shares of bluebird bio in a research note on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $100.02.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.